Advanced Hepatocellular Carcinoma (HCC) Clinical Trial
Official title:
Efficacy and Safety of HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) is widely applied and shows good efficacy in advanced hepatocellular carcinoma (HCC). Recently, hepatic arterial infusion chemotherapy (HAIC) has also gained popularity in the treatment of HCC. Several studies have described the comparison between HAIC and TACE or TACE combined with HAIC. However, the evaluation between TACE plus HAIC and HAIC is rarely reported. Here, we will evaluate the performance of HepaSphere DEB-TACE combined with HAIC (HEPA-HAIC) comparing to HAIC in patients with advanced HCC
This is a double-arm, retrospective, observational study. The patients diagnosed as advanced HCC and treated with HepaSphere plus HAIC or single HAIC in the interventional therapy department of Peking University Cancer Hospital & Institute from May 2018 to May 2022. These patients are grouped into two cohorts. One is HEPA-HAIC group, the other is HAIC group. To access the effect of HepaSphere plus HAIC and single HAIC on the treatment of advanced HCC, the treatment efficacy and safety will be analyzed between these two cohorts. To avoid the selection bias, Propensity score matching (PSM) will be also conducted. The primary endpoints are progression-free survival (PFS) and overall survival (OS); the secondary endpoint includes objective response rate (ORR), disease control rate (DCR) and safety ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04985136 -
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
|
Phase 3 | |
| Recruiting |
NCT02509169 -
Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04723004 -
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
|
Phase 3 | |
| Completed |
NCT02814461 -
The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC
|
Phase 1 | |
| Not yet recruiting |
NCT04344158 -
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
|
Phase 3 | |
| Completed |
NCT02906397 -
Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)
|
Phase 1 | |
| Active, not recruiting |
NCT04523493 -
Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC
|
Phase 3 | |
| Terminated |
NCT05375604 -
A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)
|
Phase 1 | |
| Terminated |
NCT01101906 -
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
|
Phase 2 | |
| Not yet recruiting |
NCT06309485 -
Phase 2 Study of WGI-0301 in Combination With Sorafenib for Advanced HCC
|
Phase 2 | |
| Terminated |
NCT04212221 -
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04605796 -
A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)
|
Phase 2 |